Valneva资助全球独家授权免疫联合与IC31®辅助瞄准系统进行乙

StephenW

Valneva Grants Exclusive Worldwide License to Immune Targeting Systems for the Development of Hepatitis B Vaccines in Combination with the IC31® Adjuvant

   
    Published on Thursday, 29 January 2015 09:17
   
LYON, France I January 29, 2015 I European biotechnology company Valneva SE (“Valneva”, the Company) and UK company Immune Targeting Systems (ITS) Ltd announced today that they have signed an exclusive worldwide commercial license agreement. The agreement grants Immune Targeting Systems the rights to research, develop and commercialize Hepatitis B vaccine candidates in combination with Valneva’s IC31® Adjuvant.

Thomas Lingelbach, President and Chief Executive Officer and Franck Grimaud, President and Chief Business Officer of Valneva commented, “Hepatitis B is a virulent and contagious disease and we are excited to license our IC31® vaccine Adjuvant to Immune Targeting Systems for developing a potential novel vaccine.”

Hepatitis B is a serious infection of the liver caused by the hepatitis B virus and is considered a major global health problem. According to the Hepatitis B Foundation, an estimated 1 million people worldwide die each year from Hepatitis B and ist complications. In the US alone over 12 million people have already been infected (one out of 20 people). Although there are several approved drugs to treat Chronic Hepatitis B (CHB), they only slow down the virus and rarely get rid of it completely. Identifying a functional or complete cure for hepatitis B infection remains a significant area of unmet medical need.

“The pan-genotype therapeutic vaccine for Chronic Hepatitis B (CHB) is a very promising product candidate that can potentially provide a cure for CHB sufferers in developed as well as developing countries. We are excited to team up with Valneva to advance the clinical development of this product.” Benjamin Chen, Chairman and Chief Executive Officer of Immune Targeting Systems also said.

Valneva’s IC31® Adjuvant is a unique synthetic adjuvant combining the immuno-stimulating properties of an antimicrobial peptide (KLK) and an oligodeoxynucleotide (ODN1a). Eight human clinical trials have shown IC31® to be a safe and immunogenic adjuvant in study volunteers. Those receiving IC31® have reported good local tolerance with no systemic adverse effects reported during clinical studies.

Financial terms of the agreement were not disclosed but include an upfront payment. If successful, product candidates from these agreements may lead to additional cash payments for achieved milestones along with future royalties on net sales.

About Immune Targeting Systems Ltd

Immune Targeting Systems focused on the development of T-cell vaccines to highly mutated viruses and to cancers utilizing its proprietary long-peptide based Depovaccine® platform. The company is supported by Novartis Venture Fund, HealthCap, Truffle Capital, Esperante Ventures and London SME.

About Valneva SE

Formed in 2013 through the merger of Intercell AG and Vivalis SA, Valneva is a biotechnology company developing, manufacturing and commercializing innovative vaccines with a vision to protect people from infectious diseases.

The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

Valneva´s portfolio includes a commercial vaccine for the prevention of Japanese encephalitis (IXIARO®) and proprietary vaccines in development against Pseudomonas aeruginosa, Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the company’s value proposition and include vaccines being developed using Valneva´s innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant).

Valneva is headquartered in Lyon, France, listed on Euronext-Paris and the Vienna stock exchange and operates out of France, Austria and Scotland with approximately 270 employees. More information is available at www.valneva.com.

SOURCE: Valneva

StephenW

Valneva资助全球独家授权免疫联合与IC31®辅助瞄准系统进行乙肝疫苗的发展

   
    周四公布，2015年1月29日09:17
   
法国里昂，我2015年1月29日我的欧洲生物技术公司Valneva SE（“Valneva”，本公司）和英国公司瞄准免疫系统（ITS）有限公司今天宣布，双方已经签署了一项全球独家商业授权协议。该协议授予免疫瞄准系统的权利，研究，开发和推广乙肝疫苗候选人与Valneva的IC31®辅助组合。

托马斯Lingelbach，Valneva总裁兼首席执行官弗兰克和格里莫，总裁兼首席商务官表示：“乙肝是一种致命的传染病，我们很高兴能够授权我们IC31®疫苗佐剂免疫瞄准系统为开发潜在的新疫苗。“

乙型肝炎是由乙肝病毒的肝的严重感染，被认为是一个主要的全球性健康问题。根据乙型肝炎基金会，估计有100万人在全球每年死于乙肝和IST的并发症。仅在美国，超过12万人已经感染（一出20人）。虽然有几个批准的药物来治疗慢性乙型肝炎（CHB），他们只减慢病毒很少能完全摆脱它。识别功能或完全治愈乙肝感染仍是满足医疗需要一个显著区。

“泛基因治疗疫苗治疗慢性乙型肝炎（CHB）是一个非常有前途的候选产品，可以潜在地在发达国家和发展中国家提供一种治疗慢性乙型肝炎患者。 “本杰明·陈免疫瞄准系统董事长兼首席执行官也表示，我们很高兴能与Valneva推动这一产品的临床开发。

Valneva的IC31®佐剂是一种独特的合成的佐剂组合的抗微生物肽（KLK）和一个寡核苷酸（ODN1a）的免疫刺激性质。八人体临床试验显示IC31®是在研究志愿者的安全性和免疫原性佐剂。那些接受IC31®报道良好的局部耐受性与临床研究期间报告没有全身不良影响。

没有透露该协议的财务条款，但包括预付款。如果成功的话，候选产品从这些协议可能会导致额外的现金支付以及未来的净销售额达到特许权使用费的里程碑。

关于免疫靶向系统有限公司

集中于T细胞疫苗高度突变的病毒的发展，利用其专有的长肽基Depovaccine®平台癌症免疫定位系统。该公司是由诺华风险基金，HealthCap，松露资本，Esperante Ventures和伦敦的中小企业的支持。

关于Valneva SE

通过单元间AG和VIVALIS SA合并而成，2013年，Valneva是一家生物技术公司，开发，制造和商业化创新型疫苗具有远见，以保护人们免受传染病。

本公司力求在看好的候选产品和商业产品不断增长的财政贡献，努力实现经济自立通过集中的研发投资的财务回报。

Valneva's组合包括商业日本脑炎疫苗接种（IXIARO®）和专有疫苗在发展防止对绿脓杆菌，难辨梭状芽孢杆菌和莱姆疏。使用Valneva's创新和验证的技术平台（EB66®疫苗生产株，IC31®辅助）正在开发各种与领先的制药公司的合作伙伴关系补充公司的价值主张和包括疫苗。

Valneva总部设在法国里昂，在Euronext巴黎和维也纳证券交易所上市，并经营了法国，奥地利和苏格兰拥有约270名员工。更多信息，请www.valneva.com。

来源：Valneva

MP4

又一个治疗性乙肝疫苗